CORT 125134

Drug Profile

CORT 125134

Alternative Names: CORT-125134

Latest Information Update: 03 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Corcept Therapeutics
  • Developer Corcept Therapeutics; Johns Hopkins University; National Institute on Alcohol Abuse and Alcoholism
  • Class Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cushing syndrome
  • Phase I/II Solid tumours
  • Clinical Phase Unknown Alcoholism

Most Recent Events

  • 01 Sep 2016 Corcept Therapeutics completes a phase I trial in volunteers in United Kingdom (NCT03067376)
  • 02 Aug 2016 Phase-II clinical trials in Cushing's syndrome in USA
  • 01 Aug 2016 Phase-I clinical trials in Cushing's syndrome (In volunteers) in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top